Metabolic Disease

Metabolic diseases – including diabetes, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and other metabolic and endocrine disorders – represent a major threat to public health, and the development of novel therapeutics for these indications is critical. By leveraging our drug discovery and development services, researchers can gain critical insights into the biology underlying metabolic disease and identify promising therapeutics against these conditions.

Our non-covalent screening services have been successfully applied for the discovery and characterization of small molecules binding the GLP1 receptor, a key target in Type 2 Diabetes and obesity treatment. Our RapidFire screening services support high-throughput profiling of metabolites from virtually any sample type, while our proteomic services can support metabolic disease research across a range of applications. Our team is committed to advancing your metabolic disease research with high-quality data, rapid turnaround times, and deep scientific expertise.